BEIJING – A Chinese pharmaceutical company said Thursday that the coronavirus vaccine to come will be in international distribution until early 2021, he added in the United States.
Yin Weidong, CEO of SinoVac, promised to ask the U. S. Food and Drug Administration to sell CoronaVac in the United States if it approves of its third and final human test circular. Yin testified that he had won the experimental vaccine.
“In the early days, our strategy was designed for China and Wuhan. Soon after, in June and July, we adjusted our strategy to deal with the world,” Yin said, referring to the Chinese city where the virus first appeared.
“Our purpose is to supply the vaccine to the world, adding to the US, the EU and other countries,” Yin said.
Strict regulations in the United States, the European Union, Japan and Australia have traditionally blocked the sale of Chinese vaccines, but Yin said that could change.
SinoVac is presenting one of the top 4 candidate vaccines in China with the state-owned SinoPharm, which has two in development, and the cansine Army affiliate.
More than 24,000 other people are currently participating in CoronaVac clinical trials in Brazil, Turkey and Indonesia, with more planned trials in Bangladesh and in all likelihood in Chile, Yin said. SinoVac chose these countries because they all had severe epidemics, giant populations and limited studies. and ability to progress, he said.
He spoke to reporters on a stopover at a SinoVac factory south of Beijing. Built in a few months from scratch, the plant is designed to be compatible with SinoVac to produce part of a million doses of vaccine according to the year. Busy Thursday filling small vials of vaccine and locked up. The company expects to be able to produce a few hundred million doses of the vaccine until February or March next year.
SinoVac is also starting to control small doses of CoronaVac in young people in all 3 countries due to the highest rate of infection among young people.
Yin said the company would prioritize the distribution of vaccines in countries conducting human trials of CoronaVac.
Although the vaccine has not yet passed Phase 3 clinical trials, a globally accepted standard, SinoVac has already injected thousands of others into China as a component of an emergency use provision.
Yin said he was one of the first to get the experimental vaccine months ago with researchers after stages one and two of the human trials showed no serious adverse effects.
“It’s a kind of culture of our company,” Yin said, adding that he had done the same with a vaccine against developing hepatitis.
Earlier this year, China’s legal “emergency use” of vaccine applicants for at-risk populations, such as border and medical, if corporations can show “smart protection and smart antibodies” from testing on some 1,000 people, Yin said.
SinoVac won this approval in June with SinoPharm and CanSino, and was able to supply tens of thousands of doses of CoronaVac to the Beijing municipal government, Yin said.
SinoVac workers qualified for emergency use of the vaccine because an outbreak within the company would paralyze their ability to expand a vaccine, he said. Approximately 90% of the company won it.
“We are confident that our COVI-19 vaccines can meet the criteria of the United States and EU countries,” Yin said.
——— Associated Press video manufacturer Olivia Zhang contributed to the report.
24/7 policy of the latest news and events